August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors

Sep 8, 2021 | Deal of the Month, Partnership Deals

August 2021 Top Biopharma Deal Upfront
RemeGen development and commercialization deal with Seagen for disitamab vedotin

Highlighted Deal Financial Comps

Date Announced:

August 9, 2021

Total Deal Value:

$2,600M

Upfront Cash:

$200M

Upfront Equity:

n/a

Option Payments:

n/a

Total Milestones:

$2,400M (Dev., Reg., and Sales)

Royalties:

Tiered, high single-digit to mid-teens

Cost & Profit Split:

n/a

Deal Synopsis

The Asset:

Phase II HER2-targeted ADC disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.

Deal Structure:

Development and Commercial License

Partnership Features:

Development responsibility and costs split by territory.

Deal Details:

  • RemeGen granted Seagen exclusive, worldwide rights, excluding parts of Asia, to co-develop and commercialize HER2-targeted ADC, disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
  • RemeGen will retain development and commercialization rights in Asia excluding Japan and Singapore and will be responsible for all submissions specific to its territory.
  • Seagen will lead global clinical development and RemeGen will fund and operate clinical trials attributable to its territory.
  • RemeGen will receive $200M up front and is eligible for up to $2.4B in development, regulatory, and commercialization milestones, plus undisclosed tiered, high single-digit to mid-teens royalties.

Last Month:

Congrats to RemGen and Seagen for landing the DealForma August 2021 Top Biopharma Deal of the Month. The Deal of the Month for July 2021 was Arvinas and Pfizer’s PROTAC deal with $1B up front for ARV-471. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

21,598

Licensing Deals

22,217

Funding Rounds

4,216

M&A

35,278

Company Profiles

5,897

Other Deals

27,588

Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Venture Activity In Global Healthcare & Life Sciences – 2023

Venture Activity In Global Healthcare & Life Sciences – 2023

An increase in down rounds in 2023 indicates a reassessment of valuations in VC. Challenges are expected to persist in the sector through the H1 of 2024, grappling with repercussions from previous excesses and a challenging fundraising environment. The initiation of a...